Herold N - Search Results

1

The nucleocapsid domain of Gag is dispensable for actin incorporation into HIV-1 and for association of viral budding sites with cortical F-actin.

Stauffer S, Rahman SA, de Marco A, Carlson LA, Glass B, Oberwinkler H, Herold N, Briggs JA, Müller B, Grünewald K, Kräusslich HG. Stauffer S, et al. Among authors: herold n. J Virol. 2014 Jul;88(14):7893-903. doi: 10.1128/JVI.00428-14. Epub 2014 Apr 30. J Virol. 2014. PMID: 24789788 Free PMC article.

2

HIV-1 entry in SupT1-R5, CEM-ss, and primary CD4+ T cells occurs at the plasma membrane and does not require endocytosis.

Herold N, Anders-Ößwein M, Glass B, Eckhardt M, Müller B, Kräusslich HG. Herold N, et al. J Virol. 2014 Dec;88(24):13956-70. doi: 10.1128/JVI.01543-14. Epub 2014 Sep 24. J Virol. 2014. PMID: 25253335 Free PMC article.

3

Reply to "Can HIV-1 entry sites be deduced by comparing bulk endocytosis to functional readouts for viral fusion?".

Herold N, Müller B, Kräusslich HG. Herold N, et al. J Virol. 2015 Mar;89(5):2986-7. doi: 10.1128/JVI.03376-14. J Virol. 2015. PMID: 25657215 Free PMC article. No abstract available.

4

A quantitative measure for alterations in the actin cytoskeleton investigated with automated high-throughput microscopy.

Weichsel J, Herold N, Lehmann MJ, Kräusslich HG, Schwarz US. Weichsel J, et al. Among authors: herold n. Cytometry A. 2010 Jan;77(1):52-63. doi: 10.1002/cyto.a.20818. Cytometry A. 2010. PMID: 19899129 Free article.

5

Complex Interplay between HIV-1 Capsid and MX2-Independent Alpha Interferon-Induced Antiviral Factors.

Bulli L, Apolonia L, Kutzner J, Pollpeter D, Goujon C, Herold N, Schwarz SM, Giernat Y, Keppler OT, Malim MH, Schaller T. Bulli L, et al. Among authors: herold n. J Virol. 2016 Jul 27;90(16):7469-7480. doi: 10.1128/JVI.00458-16. Print 2016 Aug 15. J Virol. 2016. PMID: 27279606 Free PMC article.

6

Effects of Inner Nuclear Membrane Proteins SUN1/UNC-84A and SUN2/UNC-84B on the Early Steps of HIV-1 Infection.

Schaller T, Bulli L, Pollpeter D, Betancor G, Kutzner J, Apolonia L, Herold N, Burk R, Malim MH. Schaller T, et al. Among authors: herold n. J Virol. 2017 Sep 12;91(19):e00463-17. doi: 10.1128/JVI.00463-17. Print 2017 Oct 1. J Virol. 2017. PMID: 28747499 Free PMC article.

7

The Early Bird Catches the Worm--Can Evolution Teach us Lessons in Fighting HIV?

Schaller T, Herold N. Schaller T, et al. Among authors: herold n. Curr HIV Res. 2016;14(3):183-210. doi: 10.2174/1570162x14999160224094914. Curr HIV Res. 2016. PMID: 26957195 Review.

8

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.

Herold N, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, Heshmati Y, Hagenkort A, Kutzner J, Page BD, Calderón-Montaño JM, Loseva O, Jemth AS, Bulli L, Axelsson H, Tesi B, Valerie NC, Höglund A, Bladh J, Wiita E, Sundin M, Uhlin M, Rassidakis G, Heyman M, Tamm KP, Warpman-Berglund U, Walfridsson J, Lehmann S, Grandér D, Lundbäck T, Kogner P, Henter JI, Helleday T, Schaller T. Herold N, et al. Nat Med. 2017 Feb;23(2):256-263. doi: 10.1038/nm.4265. Epub 2017 Jan 9. Nat Med. 2017. PMID: 28067901

9

SAMHD1 is a barrier to antimetabolite-based cancer therapies.

Rudd SG, Schaller T, Herold N. Rudd SG, et al. Among authors: herold n. Mol Cell Oncol. 2017 Feb 3;4(2):e1287554. doi: 10.1080/23723556.2017.1287554. eCollection 2017. Mol Cell Oncol. 2017. PMID: 28401188 Free PMC article.

10

SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.

Herold N, Rudd SG, Sanjiv K, Kutzner J, Bladh J, Paulin CBJ, Helleday T, Henter JI, Schaller T. Herold N, et al. Cell Cycle. 2017 Jun 3;16(11):1029-1038. doi: 10.1080/15384101.2017.1314407. Epub 2017 Apr 24. Cell Cycle. 2017. PMID: 28436707 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

91 results

Search Page